Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06GUJ
|
||||
| Former ID |
DNC007644
|
||||
| Drug Name |
KURAIDIN
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [526395] | ||
| Formula |
C26H30O6
|
||||
| Canonical SMILES |
CC(=CCC(CC1=C(C=C(C(=C1O)C(=O)C=CC2=C(C=C(C=C2)O)O)OC)O<br />)C(=C)C)C
|
||||
| InChI |
1S/C26H30O6/c1-15(2)6-7-18(16(3)4)12-20-23(30)14-24(32-5)25(26(20)31)21(28)11-9-17-8-10-19(27)13-22(17)29/h6,8-11,13-14,18,27,29-31H,3,7,12H2,1-2,4-5H3/b11-9+/t18-/m1/s1
|
||||
| InChIKey |
PIAPWPAWQGDOMN-SXAWMYDMSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | CAMP-specific 3',5'-cyclic phosphodiesterase 4A | Target Info | Inhibitor | [526395] | |
| Sodium/glucose cotransporter 1 | Target Info | Inhibitor | [528742] | ||
| CGMP-specific 3',5'-cyclic phosphodiesterase | Target Info | Inhibitor | [526395] | ||
| CGMP-inhibited 3',5'-cyclic phosphodiesterase A | Target Info | Inhibitor | [526395] | ||
| CAMP-specific 3',5'-cyclic phosphodiesterase 4B | Target Info | Inhibitor | [526395] | ||
| mRNA of sodium-glucosetransporter-2 | Target Info | Inhibitor | [528742] | ||
| KEGG Pathway | Purine metabolism | ||||
| cAMP signaling pathway | |||||
| Morphine addictionhsa04973:Carbohydrate digestion and absorption | |||||
| Bile secretion | |||||
| Mineral absorptionhsa00230:Purine metabolism | |||||
| cGMP-PKG signaling pathwayhsa00230:Purine metabolism | |||||
| cGMP-PKG signaling pathway | |||||
| Morphine addictionhsa00230:Purine metabolism | |||||
| Morphine addiction | |||||
| PathWhiz Pathway | Lactose Degradation | ||||
| Trehalose Degradation | |||||
| WikiPathways | G Protein Signaling PathwaysWP2884:NRF2 pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| Metabolism of carbohydratesWP2005:miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBaseWP35:G Protein Signaling Pathways | |||||
| Myometrial Relaxation and Contraction Pathways | |||||
| Nuclear Receptors Meta-Pathway | |||||
| Opioid SignallingWP2884:NRF2 pathway | |||||
| References | |||||
| Ref 526395 | Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. | ||||
| Ref 528742 | Bioorg Med Chem. 2007 May 15;15(10):3445-9. Epub 2007 Mar 12.Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. | ||||